There's been a lot of comments on the Charting thread regarding share price projections following the upcoming release of adult clinical study results. For the most part, I hate to burst you bubble guys but I doubt very much if we'll see some of the valuations many of you are hoping for (at least not just yet). I use the past as a predictor of the future. On 03/03/2016 RAP announced "breakthrough performance in paediatric clinical study" (see below). The closing share price was 0.13 prior to the announcement and 0.19 after the announcement, representing a 41% gain. Therefore IF adult clinical study results are as good as the paediatric clinical study results and assuming the closing share price before the announcement is 0.40, we may see a 41% gain and a closing share price of 0.56. I believe further inflation of the market cap/share price will come with commercialisation of the technology and/or FDA approval. It's worth noting that when ResApp announced "updated paediatric clinical study results" the share price went down 4%. Good luck to all, and lets try to keep the Charting thread for what it was intended. Cheers.
adult clinical studies
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #